Riboswitch-controlled IL-12 gene therapy reduces hepatocellular cancer in mice

Riboswitch-controlled IL-12 gene therapy reduces hepatocellular cancer in mice

Hepatocellular carcinoma (HCC) and solid cancers with liver metastases are indications with high unmet medical need. Interleukin-12 (IL-12) is a proinflammatory cytokine with substantial anti-tumor properties, but its therapeutic potential has not been realized due to severe toxicity. Here, we show...

Full description

Bibliographic Details
Main Authors: Matthias J. Düchs, Ramona F. Kratzer, Pablo Vieyra-Garcia, Benjamin Strobel, Tanja Schönberger, Peter Groß, Ghaith Aljayyoussi, Aradhana Gupta, Isabel Lang, Holger Klein, Sandra Martinez Morilla, Stefan Hopf, John Park, Sebastian Kreuz, Matthias Klugmann, Frederik H. Igney
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-03-01
Series:Frontiers in Immunology
Subjects:
il-12
cancer
immunotherapy
aptazyme riboswitch
inducible gene expression
regulatable gene therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1360063/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1360063/full

Similar Items